FranciscoRobert-VizcarrondoMD

Oncology • Birmingham, AL

Chief, Hematology/Oncology Birmingham VA Hospital

Join to view full profile

Are you Dr. Vizcarrondo?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
2000 6th Ave S
Birmingham, AL 35233
Phone+1 205-934-9999

Summary

Dr. Francisco Vizcarrondo, MD is an oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama. He is affiliated with University of Alabama Hospital and is a Chief at Hematology/Oncology Birmingham VA Hospital.

Education & Training

University of Puerto RicoFellowship, Hematology and Medical Oncology, 1974 - 1976
University of Puerto Rico School of MedicineClass of 1969

Certifications & Licensure

AL State Medical License 1974 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours Start of enrollment: 2018 May 03
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

12 citations
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Khanh T. Do, Laura Q.M. Chow, Karen L. Reckamp, Rachel E. Sanborn, Howard A. Burris
The Oncologist. 2021-11-01
16 citations
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation...
Jeffrey M. Clarke, Jyoti D. Patel, Francisco Robert, Ebenezer A. Kio, Eddie Thara
Lung Cancer. 2021-09-17
7 citations
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
Hossein Borghaei, Mary W. Redman, Karen Kelly, Saima N. Waqar, Francisco Robert
Clinical Lung Cancer. 2021-05-01